> Autolus completed the first-dose cohort in a phase 1/2 trial of its CAR-T candidate. The multiple myeloma trial will provide an early test of its dual-targeting approach to CAR-T, which makes two changes to patients’ T cells in an attempt to stop tumors evading detection. Statement | FT
> Cell Medica named Luis Borges, Ph.D., as its CSO. Borges joins the T cell biotech from Five Prime Therapeutics, where he rose through the ranks to the position of SVP of research before making way for Bryan Irving, Ph.D. Release
> European regulators rejected AB Science’s masitinib for the second time in 16 months. The latest rejection followed a reassessment of the evidence to support use of the drug in adult patients with smoldering or indolent systemic severe mastocytosis. AB shares slipped more than 20% in the days following the news. Statement
> Pharnext changed the protocol of its phase 3 Charcot-Marie-Tooth disease type 1A trial. The trial will now give patients in the high-dose arm of the trial’s nine-month extension double the amount of the low dose, not the high-dose formulation. Pharnext made the change after learning of stability problems with the high-dose formulation. Release
> Enterome unveiled plans to move its research laboratories to the Genopole biocluster. The move will affect 15 of the microbiome specialist's 40 employees. Statement
> Life sciences crowdfunding platform Capital Cell opened up to investors in the U.K. Release